The US Food and Drug Administration (FDA) has approved Cumberland Pharmaceuticals’ methotrexate products to treat adult and paediatric patients with rheumatoid arthritis, as well as adults with psoriasis.

To secure the approval for the RediTrex product line, Cumberland communicated with the FDA various times, making several amendments to the new drug application (NDA) submitted to the US regulator in late 2018.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In the US, methotrexate is approved as both an oral and injectable treatment. In comparison to oral formulations, injectable methotrexate results in increased efficacy, better continuation rates and less discomfort for patients.

Cumberland’s methotrexate products offer improvements and patient benefits when compared to conventional injectable methotrexate products presently available in the US.

The company has secured exclusive US commercial rights to European pharmaceutical company Nordic Group’s injectable methotrexate line of products.

Cumberland Pharmaceuticals CEO AJ Kazimi said: “We are delighted by the FDA approval of RediTrex for the United States.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We are looking forward to bringing this important product to the patients seeking an easy-to-use methotrexate injectable.”

Cumberland is set to introduce two injectable methotrexate product lines within the US to treat active rheumatoid arthritis, juvenile idiopathic arthritis and severe psoriasis.

Cumberland acquires, develops and commercialises branded prescription products to enhance quality of care and address unmet medical requirements.

The company also makes its products available to patients globally via select partnerships.

Some of the company’s portfolio of FDA approved brands include Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, as well as Caldolor (ibuprofen) Injection, for the treatment of pain and fever and Kristalose (lactulose) Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact